Company Name
SCONRY Biopharma(Shanghai)Co.,Ltd
Year of Establishment
2022
Annual Turnover(USD)
500,000 to 99,999,999
Company Introduction
We focus on synthetic biology technology research and development and industrial application, with "from nature, for nature" as the core concept, to build a full chain system from molecular design to large-scale production. Relying on core technologies such as enzyme engineering, gene editing, and cell fermentation, the company develops products such as microbial drug raw materials, biological pesticides, and food additives to help the low-carbon transformation of medicine, agriculture, and chemical industries.
Main Competitive Advantages
Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Website
http://www.cell-freebiopharma.com/
Other Competitive Advantages
Unique Technology: "Reverse" genetic modification and "glycolysis" enzyme libraries accelerate the creation and transformation of chassis organisms
Industry Leading: Compared with the industry, we have a "0" enzyme catalytic cost, and the yield and industrial scale far exceed those of our peers, and the unit cost is greatly reduced.
Patents and Copyright
At present, we have over 20 types of invention patents on public display. If you need to check the details, please search by yourself.
Milestone
June 2022: Sikangrui Biomedicine (Shanghai) Co., Ltd. was established.
January 2023: Project construction of enzyme library platform.
May 2023: Completed the research and development of the production process of phosphine ammonium and 5-aminolevulinic acid.
November 2023: The 5-aminolevulinic acid 60-ton system was put into production, with a output of up to 58g/L.
December 2023: Arecoline hydrobromide production; In the same year, a number of raw materials were developed: resveratrol, Fusidic acid, calcium propionate, etc.
July 2024: Completed Pre-A round of financing, which was jointly invested by Mr. He Haichao, chairman of Jinwei Machinery and Chairman of Jinwei Fund, and Mr. Xie Youbang and Mr. Fang Ying, founding partners of Jinwei Fund.
October 2024: Established horizontal cooperation with the team of Professor Zha Jian and Professor Wu Xia of Shaanxi University of Science and Technology.
November 2024: Completion of the new R&D platform; The enzyme library was expanded to 3000+ and the reaction types were 30+.
December 2024: The production process of refined ammonium phosphonase catalytic process (powder, mother liquor) was put into stable operation, and a number of leading agrochemical enterprises reached cooperation.